Related Articles
Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
Personalized peptide vaccination in patients with refractory non-small cell lung cancer
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer